1 / 16

Chemical Genomics – Biol503

Chemical Genomics – Biol503 . Lecture 2 Chemical Genomics and cancer/cardiovascular diseases. Anticancer Drug Screen. Traditional Approach: cell growth inhibition. Screen of synthetic and natural product compound libraries for inhibitor of cancer cell-lines NCI’s cancer cell-lines (free)

davida
Download Presentation

Chemical Genomics – Biol503

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

  2. Anticancer Drug Screen

  3. Traditional Approach: cell growth inhibition • Screen of synthetic and natural product compound libraries for inhibitor of cancer cell-lines • NCI’s cancer cell-lines (free) • NCI’s Open Chemical Repository Collection (140,000 compounds) • NCI’s Natural Products Repository

  4. Protein Kinases – cancer and cardiovascular diseases

  5. Cancer Pathways – cellular targets Source: Prous Integrity

  6. Phosphorylation • Phosphorylation by protein kinases is the most widespread and well-studied signal mechanisms in eukaryotic cells • Kinome: 518 kinases, each phosporylates a distinct set of substrates • Understanding complex network of kinase-based signaling is important for cancer and cardiovascular diseases

  7. Kinase assay – an exampleTime resolved FRET

  8. Approved drug: an example • Tykerb (lapatinib ditosylate) is an EGFR and ErbB-2 dual tyrosince kinase inhibitor. • EGFR- epidermal growth factor receptor • ErbB-2 (HER2/neu) – Human Epidermal growth factor Receptor 2 • Developed by GlaxoSmithKline • Approved by FDA March 2007 for use in combination with capectabine for patients with advanced, metastatic breast cancer that is HER2 positive.

  9. Protein Tyrosine Phosphatases – cancer and cardiovascular diseases

  10. Protein tyrosince phosphatases • The PTP superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signal pathways • Regulatory role of protein kinases well established. • But protein phosphatases can no longer viewed as passive housekeeping enzymes in the processes.

  11. Diversity of PTPs

  12. Regulation by dimerization

  13. Regulation by Ligands

  14. PTPs and Cancers

  15. ProFluor Assay

  16. References • Johnson and Hunter, Nature Methods, 2005 • N.K. Tonks, Nature Review Mol Cell Biol, 2006

More Related